Search Result

Results for "

progenitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (5) Arrestin (2) Bcr-Abl (1) c-Fms (4) Caspase (1) CCR (1) CXCR (4) DYRK (1) Epigenetic Reader Domain (1) Flavivirus (1) FLT3 (1) Formyl Peptide Receptor (FPR) (1) Glutathione S-transferase (2) GPR68 (1) GSK-3 (1) Hedgehog (1) Integrin (3) JAK (1) MAP4K (26) Microtubule/Tubulin (1) Monoamine Oxidase (2) Organoid (1) Phosphatase (1) RAR/RXR (1) Reactive Oxygen Species (1) ROCK (1) Smo (1) Src (1) STAT (1) Wnt (2) β-catenin (2)
By Research Areas:	Cancer (43) Cardiovascular Disease (2) Endocrinology (3) Infection (2) Inflammation/Immunology (25) Metabolic Disease (1) Neurological Disease (9)

By Targets:

Antibiotic (1)

Apoptosis (5)

Arrestin (2)

Bcr-Abl (1)

c-Fms (4)

Caspase (1)

CCR (1)

CXCR (4)

DYRK (1)

Epigenetic Reader Domain (1)

Flavivirus (1)

FLT3 (1)

Formyl Peptide Receptor (FPR) (1)

Glutathione S-transferase (2)

GPR68 (1)

GSK-3 (1)

Hedgehog (1)

Integrin (3)

JAK (1)

MAP4K (26)

Microtubule/Tubulin (1)

Monoamine Oxidase (2)

Organoid (1)

Phosphatase (1)

RAR/RXR (1)

Reactive Oxygen Species (1)

ROCK (1)

Smo (1)

Src (1)

STAT (1)

Wnt (2)

β-catenin (2)

By Research Areas:

Cancer (43)

Cardiovascular Disease (2)

Endocrinology (3)

Infection (2)

Inflammation/Immunology (25)

Metabolic Disease (1)

Neurological Disease (9)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145107

HPK1-IN-19

MAP4K Inflammation/Immunology Cancer

HPK1-IN-19 is a hematopoietic progenitor kinase 1 (HPK1) inhibitor extracted from patent WO2018102366A1 compound I-47 .
HY-113845

(+)-Intermedine

Others Neurological Disease

(+)-Intermedine, a pyrrolizidine alkaloid (PA), exhibits significant cytotoxicity in neural progenitor cells (NPCs) .
HY-145109

HPK1-IN-20

MAP4K Inflammation/Immunology Cancer

HPK1-IN-19 is a hematopoietic progenitor kinase 1 (HPK1) inhibitor extracted from patent WO2020235902A1 compound 106 .

HPK1-IN-19	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-19 is a *hematopoietic progenitor* kinase 1 (HPK1)** inhibitor extracted from patent WO2018102366A1 compound I-47 .

(+)-Intermedine	Others	Neurological Disease
(+)-Intermedine, a pyrrolizidine alkaloid (PA), exhibits significant cytotoxicity in neural progenitor cells (NPCs) .

HPK1-IN-20	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-19 is a *hematopoietic progenitor* kinase 1 (HPK1)** inhibitor extracted from patent WO2020235902A1 compound 106 .

HY-145041

HPK1-IN-15	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-15 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-15 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2018049200A1, compound 50) .

HY-145042

HPK1-IN-16	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-16 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-16 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2019051199A1, compound 39) .

HY-145044

HPK1-IN-17	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-17 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-17 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2019238067A1, compound 73) .

HY-145045

HPK1-IN-18	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-18 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-18 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2019238067A1, compound 1) .

HY-113845R

(+)-Intermedine (Standard)	Others	Neurological Disease
(+)-Intermedine (Standard) is the analytical standard of (+)-Intermedine. This product is intended for research and analytical applications. (+)-Intermedine, a pyrrolizidine alkaloid (PA), exhibits significant cytotoxicity in neural progenitor cells (NPCs) .

HY-144091

HPK1-IN-24

MAP4K Cancer

HPK1-IN-24 (example 51) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with a K_i of 100 nM. HPK1-IN-24 has the potential for cancer research .

HPK1-IN-24	MAP4K	Cancer
HPK1-IN-24 (example 51) is a *hematopoietic progenitor* kinase 1 (HPK1) inhibitor with a K_i** of 100 nM. HPK1-IN-24 has the potential for cancer research .

HY-13973A

GSK-3 inhibitor 1 1 Publications Verification	GSK-3	Metabolic Disease
GSK-3 inhibitor 1 (compound core 3) is a GSK-3 inhibitor that induces stem/progenitor cell self-renewal (e.g. induces stem/progenitor cell proliferation while maintaining the ability to differentiate into tissue cells in the progeny) .

HY-144092

HPK1-IN-25	MAP4K	Cancer
HPK1-IN-25 (example 94) is a *hematopoietic progenitor* kinase 1 (HPK1) inhibitor with a enzymatic activity IC₅₀** of 129 nM. HPK1-IN-25 has the potential for cancer research .

HY-B0534

Moclobemide Ro111163	Monoamine Oxidase	Neurological Disease
Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC₅₀ of 6.061 μM for hMAO-A .Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.

HY-135892

GNE-1858 1 Publications Verification	MAP4K	Inflammation/Immunology
GNE-1858 is a potent and ATP-competitive *hematopoietic progenitor* kinase-1 (HPK1) inhibitor, with IC₅₀**s of 1.9 nM, 1.9 nM, and 4.5 nM for wild-type and the active mimetic mutants HPK1-TSEE and HPK1-SA, respectively .

HY-107589A

BIO5192 hydrate 1 Publications Verification	Integrin	Inflammation/Immunology
BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (K_d<10 pM). BIO5192 hydrate selectively binds to α4β1 (IC₅₀=1.8 nM) over a range of other integrins. BIO5192 hydrate results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .

HY-107589

BIO5192 1 Publications Verification	Integrin	Inflammation/Immunology
BIO5192 is a selective and potent integrin α4β1 (VLA-4) inhibitor (K_d<10 pM). BIO5192 selectively binds to α4β1 (IC₅₀=1.8 nM) over a range of other integrins. BIO5192 results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels .

HY-129453

BOP sodium	Integrin	Inflammation/Immunology
BOP sodium is a potent and selective dual α9β1/α4β1 integrin inhibitor with K_d values in the picomolar range. BOP sodium shows the rapid and preferential mobilization of hematopoietic stem cell (HSC) and progenitors. BOP sodium has little inhibitory activity on α4β7, α1β1, α2β1, and α5β1, αIIBβ3 integrins .

HY-145036

HPK1-IN-10	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-10 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-10 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 103) .

HY-145037

HPK1-IN-11	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-11 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-11 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 2) .

HY-145038

HPK1-IN-12	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-12 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-12 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 85) .

HY-145039

HPK1-IN-13	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-13 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-13 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 64) .

HY-145040

HPK1-IN-14	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-14 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-14 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 79) .

HY-145035

HPK1-IN-9	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-9 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-9 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 112) .

HY-W127530

α-Tocopherol phosphate disodium 3 Publications Verification alpha-Tocopherol phosphate disodium; TocP disodium; Vitamin E phosphate disodium	Apoptosis Reactive Oxygen Species	Cardiovascular Disease
α-Tocopherol phosphate (alpha-Tocopherol phosphate) disodium, a promising antioxidant, can protect against long-wave UVA1 induced cell death and scavenge UVA1 induced ROS in a skin cell model. α-Tocopherol phosphate disodium possesses therapeutic potential in the inhibition of apoptosis and increases the migratory capacity of endothelial progenitor cells under high-glucose/hypoxic conditions and promotes angiogenesis .

HY-108476

INDY 2 Publications Verification	DYRK	Cancer
INDY is a potent and ATP-competitive Dyrk1A and Dyrk1B inhibitor with IC₅₀s of 0.24 μM and 0.23 μM, respectively. INDY binds in the ATP pocket of the enzyme and has a K_i value of 0.18 μM for Dyrk1A. INDY sharply reduces the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells .

HY-10591

Neuropathiazol	Others	Neurological Disease
Neuropathiazol, a neuronal differentiation inducer, selectively induces neuronal differentiation of multipotent hippocampal neural progenitor cells .

HY-100670

Olinone	Epigenetic Reader Domain	Neurological Disease
Olinone is a selective BRD4 BrD1 inhibitor . Olinone accelerates the progression of mouse primary oligodendrocyte progenitors toward differentiation .

HY-103361

SB297006 1 Publications Verification	CCR	Neurological Disease Endocrinology
SB297006 is a CCR3 antagonist, which significantly inhibits proliferation and neurosphere formation in CCL11-treated neural progenitor cells.

HY-B1941

4-tert-Octylphenol
4-tert-Octylphenol, a endocrine-disrupting chemical, is an estrogenic agent. 4-tert-Octylphenol induces apoptosis in neuronal progenitor cells in offspring mouse brain. 4-tert-Octylphenol reduces bromodeoxyuridine (BrdU), mitotic marker Ki67, and phospho-histone H3 (p-Histone-H3), resulting in a reduction of neuronal progenitor proliferation. 4-tert-Octylphenol disrupts brain development and behavior in mice .

HY-10396

Emricasan 25+ Cited Publications PF 03491390; IDN-6556	Caspase Flavivirus	Infection Neurological Disease Cancer
Emricasan (PF 03491390) is an orally active and irreversible pan-caspase inhibitor. Emricasan inhibits Zika virus (ZIKV)-induced increases in caspase-3 activity and protected human cortical neural progenitors .

HY-144088

ZYF0033 HPK1-IN-22	MAP4K	Inflammation/Immunology Cancer
ZYF0033 is effective in inhibiting hematopoietic progenitor cells HPK1, basically inhibiting MBP protein oxidation IC₅₀ 10 nM . ZYF0033 promotes anti-cancer immune response, lowers SLP76 (acid 376) oxidation. ZYF0033 Suppression 4T-1 Small mouse model with the same underlying cause, medium bulge growth length expansion DC, NK 细细和 CD107a ^{+ CD8 ⁺ T Cells, PD-1 ⁺CD8 ⁺ T Cells, TIM-3 ⁺CD8 ⁺ T Cells LAG3< sup>+}CD8 ⁺ T Cellular immersion decreases.

HY-B0534S1

Moclobemide-d4 Ro111163-d₄	Monoamine Oxidase	Neurological Disease
Moclobemide-d₄ is deuterium labeled Moclobemide. Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 μM for hMAO-A[1].Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.

HY-152257

HPK1-IN-31	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-31 (compound 5i) is an orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC₅₀ value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunoresearch .

HY-P99913

Eflapegrastim	c-Fms	Inflammation/Immunology
Eflapegrastim is a human IgG4 monoclonal antibody, is also a granulocyte colony-stimulating factor (G-CSF). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .

HY-153362

HPK1-IN-34	MAP4K	Cancer
HPK1-IN-34 (Compound 143) is a Hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC₅₀ of <100 nM . HPK1-IN-34 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-138568

HPK1-IN-3	MAP4K	Inflammation/Immunology
HPK1-IN-3 is a potent and selective ATP-competitive *hematopoietic progenitor* kinase 1 (HPK1; MAP4K1) inhibitor with an IC₅₀** of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC₅₀ of 108 nM in human peripheral blood mononuclear cells (PBMCs) .

HY-149206

HPK1-IN-33	MAP4K	Cancer
HPK1-IN-33 (compound 21) is a potent *Hematopoietic Progenitor* Kinase 1 (HPK1) inhibitor with a K_i** value of 1.7 nM. HPK1-IN-33 inhibits the produce of IL-2 with EC₅₀s of 286, >10000 nM in Jurkat WT and Jurkat HPK1 KO cells, respectively .

HY-13634

Ezatiostat hydrochloride TER199; TLK199 hydrochloride	Glutathione S-transferase Apoptosis	Cancer
Ezatiostat hydrochloride (TER199; TLK199 hydrochloride) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat hydrochloride leads to JNK activation by inhibiting GSTP1. Ezatiostat hydrochloride stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat hydrochloride has the potential for myelodysplastic syndrome (MDS) treatment .

HY-13634A

Ezatiostat 3 Publications Verification TER199(free base); TLK199	Glutathione S-transferase Apoptosis	Cancer
Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment .

HY-12319A

Cardiogenol C hydrochloride	β-catenin Wnt	Cardiovascular Disease
Cardiogenol C hydrochloride is a potent cell-permeable pyrimidine inducer which prompts the differentiation of ESCs into cardiomyocytes (EC₅₀=100 nM) . Cardiogenol C hydrochloride also acts cardiomyogenic on already lineage-committed progenitor cell types with a limited degree of plasticity. Cardiogenol C hydrochloride is a useful cardiomyogenic agent and can be used as a tool to improve cardiac repair by cell transplantation therapy in animal models .

HY-12319

Cardiogenol C	β-catenin Wnt	Cancer
Cardiogenol C is a potent cell-permeable pyrimidine inducer which prompts the differentiation of ESCs into cardiomyocytes (EC₅₀=100 nM) . Cardiogenol C also acts cardiomyogenic on already lineage-committed progenitor cell types with a limited degree of plasticity. Cardiogenol C is a useful cardiomyogenic agent and can be used as a tool to improve cardiac repair by cell transplantation therapy in animal models .

HY-N3540

Caraphenol A	Others	Inflammation/Immunology
Caraphenol A is a resveratrol trimer and is able to transiently reduce interferon-induced transmembrane (IFITM) protein expression. Caraphenol A safely enhances lentiviral vector gene delivery to hematopoietic stem and progenitor cells . Caraphenol A also inhibits human cystathionine β-synthase (hCBS) and human cystathionine γ- lyase (hCSE) with IC₅₀s of 5.9 μM and 12.1 μM, respectively .

HY-132150A

HPK1-IN-2 dihydrochloride	MAP4K FLT3 Src	Cancer
HPK1-IN-2 dihydrochloride is a potent and orally active *hematopoietic progenitor* kinase-1 (HPK1) inhibitor (IC₅₀<0.05 µΜ) with antitumor activity. HPK1-IN-2 dihydrochloride also inhibits Lck (0.05 µΜ<IC₅₀<0.5 µΜ) and Flt3 (IC₅₀**<0.05 µΜ) kinase activities .

HY-143868

HPK1-IN-27	MAP4K	Cancer
HPK1-IN-27 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-27 has the potential for the research of cancer diseases (extracted from patent WO2019016071A1, compound 38) .

HY-143871

HPK1-IN-30	MAP4K	Cancer
HPK1-IN-30 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-30 has the potential for the research of cancer diseases (extracted from patent WO2021175271A1, compound 3) .

HY-P1682

Balixafortide POL6326	CXCR Arrestin	Cancer
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-P1122

Cyclosporin H 1 Publications Verification	Formyl Peptide Receptor (FPR)	Infection Inflammation/Immunology
Cyclosporin H is a selective and potent inhibitor of FPR-1 (formyl peptide receptor 1). Cyclosporin H, a viral transduction enhancer, increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs). Cyclosporin H displays an additive effect when combined with Rapamycin (HY-10219) or Prostaglandin E2 (HY-101952). Cyclosporin H lacks immunosuppressant activity of Cyclosporin A.

HY-143869

HPK1-IN-28	MAP4K	Cancer
HPK1-IN-28 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-28 enhances the body's anti-tumor immunity. HPK1-IN-28 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 1) .

HY-143870

HPK1-IN-29	MAP4K	Cancer
HPK1-IN-29 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-29 enhances the body's anti-tumor immunity. HPK1-IN-29 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 38) .

HY-147615

CSF1R-IN-12	c-Fms	Cancer
CSF1R-IN-12 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-12 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 1) .

HY-147616

CSF1R-IN-13	c-Fms	Cancer
CSF1R-IN-13 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-13 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 32) .

Cat. No.	Product Name	Target	Research Area

HY-129283A

Goralatide TFA	Peptides	Cancer
Goralatide TFA is an inhibitor of cell cycle progression. Goralatide TFA enhances selectivity of hyperthermic purging of human progenitor cells. Goralatide TFA has the potential for the research of leukemia .

HY-13634A

Ezatiostat 3 Publications Verification TER199(free base); TLK199	Glutathione S-transferase Apoptosis	Cancer
Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment .

HY-P1122

Cyclosporin H 1 Publications Verification	Formyl Peptide Receptor (FPR)	Infection Inflammation/Immunology
Cyclosporin H is a selective and potent inhibitor of FPR-1 (formyl peptide receptor 1). Cyclosporin H, a viral transduction enhancer, increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs). Cyclosporin H displays an additive effect when combined with Rapamycin (HY-10219) or Prostaglandin E2 (HY-101952). Cyclosporin H lacks immunosuppressant activity of Cyclosporin A.

HY-13634

Ezatiostat hydrochloride TER199; TLK199 hydrochloride	Glutathione S-transferase Apoptosis	Cancer
Ezatiostat hydrochloride (TER199; TLK199 hydrochloride) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat hydrochloride leads to JNK activation by inhibiting GSTP1. Ezatiostat hydrochloride stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat hydrochloride has the potential for myelodysplastic syndrome (MDS) treatment .

HY-P1682

Balixafortide POL6326	CXCR Arrestin	Cancer
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-P1682A

Balixafortide TFA 1 Publications Verification POL6326 TFA	CXCR Arrestin	Cancer
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-P0172A

ATI-2341 TFA 2 Publications Verification	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-P0172

ATI-2341	CXCR	Inflammation/Immunology Endocrinology Cancer
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .

HY-P5982

PTPσ Inhibitor, ISP	Phosphatase	Neurological Disease
PTPσ Inhibitor, ISP can bind to recombinant human PTPs and inhibits PTPσ signaling. PTPσ Inhibitor, ISP can penetrate the membrane and relieves the chondroitin sulfate proteoglycan (CSPG)-mediated axonal sprouting inhibition in spinal cord injury model. PTPσ Inhibitor, ISP enhances remyelination in LPC-induced demyelinated spinal cord. PTPσ Inhibitor, ISP also promotes oligodendrocyte progenitor cells (OPCs) migration, maturation, remyelination, and functional recovery in animal models of Multiple Sclerosis (MS) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113845

(+)-Intermedine	Alkaloids Pyrrole Alkaloids Source classification Plants Symphytum officinale L. Boraginaceae	Others
(+)-Intermedine, a pyrrolizidine alkaloid (PA), exhibits significant cytotoxicity in neural progenitor cells (NPCs) .